Reddy S V Krishna, Shaik Ahammad Basha, Bokkisam Suneel
Department of Urology, Narayana Medical College and Hospital, Nellore, India.
Department of Community Medicine and Biostatistics, Narayana Medical College and Hospital, Nellore, India.
Korean J Urol. 2014 Jun;55(6):411-6. doi: 10.4111/kju.2014.55.6.411. Epub 2014 Jun 16.
To study the effects of long-term treatment with potassium magnesium citrate and vitamin B-6 prophylaxis (Urikind-KM6; 1,100-mg potassium citrate, 375-mg magnesium citrate, and 20-mg pyridoxine hydrochloride/5 mL) every 8 hours over 3 years.
A total of 247 patients with recurrent idiopathic hypocitraturia with or without hyperuricosuria and randomized controls were studied prospectively for 3 years. The total patients were divided into three groups. Control group 1 consisted of 61 patients (24.7%) who had moderate to severe hypocitraturia with or without hyperuricosuria and were recurrent stone formers but discontinued prophylaxis because of drug intolerance within 1 month of therapy. Control group 2 constituted 53 patients (21.5%) who were first-time stone formers and who had mild hypocitraturia with or without hyperuricosuria and were not put on prophylactic therapy and were followed for 3.16±0.08 years. Control group 3 constituted 133 patients (54.8%) who were recurrent stone formers who had moderate to severe hypocitraturia with or without hyperuricosuria and were put on prophylaxis therapy and were followed for 3.16±0.08 years. All patients were followed up at 6-month intervals.
Potassium magnesium citrate prophylaxis produced a sustained increase in 24-hour urinary citrate excretion from initially low values (221.79±13.39 mg/dL) to within normal to high limits (604.04±5.00 mg/dL) at the 6-month follow-up. Urinary pH rose significantly from 5.62±0.2 to 6.87±0.01 and was maintained at 6.87±0.01. The stone recurrence rate declined from 3.23±1.04 per patient per year to 0.35±0.47 per patient per year.
Potassium magnesium citrate prophylaxis was effective in reducing the recurrence of calcium oxalate and phosphate urolithiasis.
研究每8小时服用枸橼酸钾镁和维生素B - 6预防剂（Urikind - KM6；每5毫升含1100毫克枸橼酸钾、375毫克枸橼酸镁和20毫克盐酸吡哆醇）进行3年长期治疗的效果。
对总共247例复发性特发性低枸橼酸尿症患者（伴或不伴高尿酸尿症）及随机对照患者进行了为期3年的前瞻性研究。全部患者分为三组。对照组1由61例患者（24.7%）组成，这些患者有中度至重度低枸橼酸尿症（伴或不伴高尿酸尿症），是复发性结石形成者，但在治疗1个月内由于药物不耐受而停止预防治疗。对照组2由53例患者（21.5%）组成，这些患者是首次结石形成者，有轻度低枸橼酸尿症（伴或不伴高尿酸尿症），未接受预防治疗，随访3.16±0.08年。对照组3由133例患者（54.8%）组成，这些患者是复发性结石形成者，有中度至重度低枸橼酸尿症（伴或不伴高尿酸尿症），接受预防治疗，随访3.16±0.08年。所有患者每6个月随访一次。
枸橼酸钾镁预防治疗使24小时尿枸橼酸排泄量从最初的低值（221.79±13.39毫克/分升）持续增加，在6个月随访时达到正常至高值范围（604.04±5.00毫克/分升）。尿液pH值从5.62±0.2显著升至6.87±0.01，并维持在6.87±0.01。结石复发率从每年每位患者3.23±1.04次降至每年每位患者0.35±0.47次。
枸橼酸钾镁预防治疗对降低草酸钙和磷酸盐尿路结石的复发有效。
